Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,827 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01585649 | PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma | completed | Phase 1 | 21 | Merckle GmbHINDUSTRY | 6 | May 18, 2016 | clinicaltrials |
| NCT01585987 | An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy | completed | Phase 2 | 143 | Bristol-Myers SquibbINDUSTRY | 12 | May 17, 2016 | clinicaltrials |
| NCT01151046 | Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer | completed | Phase 2 | 118 | Merrimack PharmaceuticalsINDUSTRY | 5 | May 12, 2016 | clinicaltrials |
| NCT00625664 | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer(CILAB) | completed | Phase 3 | 337 | SanofiINDUSTRY | 19 | May 5, 2016 | clinicaltrials |
| NCT02728492 | Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | completed | Phase 1 | 51 | NewVac LLCINDUSTRY | 1 | May 3, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02283320 | A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer | completed | Phase 2 | 69 | BIND TherapeuticsINDUSTRY | 2 | Apr 18, 2016 | clinicaltrials |
| NCT01792479 | A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 64 | BIND TherapeuticsINDUSTRY | 2 | Apr 15, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT00338247 | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | approved for marketing | — | — | NovartisINDUSTRY | 45 | Apr 6, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT00347919 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 2 | 189 | GlaxoSmithKlineINDUSTRY | 16 | Feb 25, 2016 | clinicaltrials |
| NCT00455533 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | completed | Phase 2 | 384 | Bristol-Myers SquibbINDUSTRY | 15 | Feb 24, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT00961415 | AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 376 | Hoffmann-La RocheINDUSTRY | 12 | Feb 22, 2016 | clinicaltrials |
| NCT02072967 | Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | completed | — | 97 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT00789828 | Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)(EXIST-1) | completed | Phase 3 | 117 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 3, 2016 | clinicaltrials |
| NCT00526669 | Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib | completed | Phase 2 | 68 | GlaxoSmithKlineINDUSTRY | 6 | Jan 29, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT00124566 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | completed | Phase 2 | 135 | Eisai Inc.INDUSTRY | 9 | Jan 18, 2016 | clinicaltrials |
| NCT01561443 | LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer(LINE) | completed | — | 153 | AstraZenecaINDUSTRY | 1 | Jan 11, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01263886 | Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer(DISRUPT) | completed | Phase 2 | 176 | SanofiINDUSTRY | 13 | Dec 21, 2015 | clinicaltrials |
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer(PERSEUS) | completed | Phase 2 | 180 | EMD SeronoINDUSTRY | 12 | Dec 14, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00879333 | Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)(GRANITE-1) | completed | Phase 3 | 656 | Novartis PharmaceuticalsINDUSTRY | 22 | Nov 3, 2015 | clinicaltrials |
| NCT01672671 | BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 3, 2015 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 | clinicaltrials |
| NCT01569815 | Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function | completed | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 3 | Oct 19, 2015 | clinicaltrials |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | terminated | Phase 2 | 255 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT01004081 | Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | completed | Phase 2 | 54 | BiogenINDUSTRY | 4 | Oct 2, 2015 | clinicaltrials |
| NCT01765569 | A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 29 | Hoffmann-La RocheINDUSTRY | 5 | Sep 23, 2015 | clinicaltrials |
| NCT00373425 | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors(RADIANT) | completed | Phase 3 | 1,252 | OSI PharmaceuticalsINDUSTRY | 19 | Sep 17, 2015 | clinicaltrials |
| NCT00902291 | A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 5 | Sep 14, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials